Skip to main content
In stock | Targeted Therapy (Investigational)

Elenestinib

Oncology Type Hematologic
Drug Class / Mechanism Next-Generation KIT D816V Inhibitor
No Image
Description

Elenestinib is classified as a Next-Generation KIT D816V Inhibitor, sourced for use within our Targeted Therapy (Investigational) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Targeted Therapy (Investigational)
Oncology Type Hematologic

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3